Navigation Links
deCODE Conducting Strategic Review to Sharpen the Focus of its Long-term Business

REYKJAVIK, Iceland, Oct. 15 /PRNewswire-FirstCall/ -- deCODE genetics (Nasdaq: DCGN) today announced that the company is carrying out a review of its long-term business strategy. Over the past few years deCODE has utilized its capabilities in medicinal chemistry, structural biology and human genetics to develop product and intellectual property portfolios in both therapeutics and DNA-based diagnostics. The goal of this strategic review is to optimize the value of these assets for its shareholders by sharpening the focus of its business, selling non-core assets, securing strategic partnerships, and utilizing the resources generated to underpin product development and marketing efforts in its core business. The company has engaged the Stanford Group Company to assist in evaluating deCODE's strategic alternatives and in executing swiftly on the results of this review through the identification of buyers and partners for non-core business units, programs and intellectual property. deCODE plans to provide an update on this process in its third quarter financial results conference call to be webcast live on November 6.

deCODE also announced that in order to provide more time for the completion of this review and the execution of alternatives including the sale of assets, it has elected to utilize a 30-day grace period for the scheduled October 15 interest payment on its outstanding 3.5% Senior Convertible Notes due 2011.

"We are in the process of creating a smaller, leaner deCODE that will devote its efforts and resources to one line of business. We have created a unique and growing portfolio of intellectual property, as well as a range of products and programs in both our drug development and diagnostics work, and are engaged in discussions with potential partners and purchasers for various programs and business units. We have engaged Stanford Group Company to assist us in in this task, with the aim of finding the best means of advancing the interests of our investors and realizing the potential of deCODE's assets and capabilities," said Kari Stefansson, CEO of deCODE.

About deCODE

deCODE is a biopharmaceutical company applying its discoveries in human genetics and its capabilities in chemistry and structural biology to the development of drugs and diagnostics for common diseases. deCODE's therapeutics programs include DG041, an antiplatelet compound being developed for the prevention of arterial thrombosis; DG051 and DG031, compounds targeting the leukotriene pathway for the prevention of heart attack; and DG071 and a platform for other PDE4 modulators with therapeutic applications in Alzheimer's disease and other conditions. Through its CLIA-registered laboratory, deCODE is offering a growing range of DNA-based tests for gauging risk and empowering prevention of common diseases, including deCODE T2(TM) for type 2 diabetes; deCODE AF(TM) for atrial fibrillation and stroke; deCODE MI(TM) for heart attack; deCODE ProCa(TM) for prostate cancer; deCODE Glaucoma(TM) for a major type of glaucoma; and deCODE BreastCancer(TM) for the common forms of breast cancer. deCODE is delivering on the promise of the new genetics.SM Visit us on the web at; on our diagnostics site at; for our pioneering personal genome analysis service, integrating the genetic variants included in these tests and those linked to another twenty common diseases, at; and on our blog at

Any statements contained in this presentation that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results, and the timing of events, to differ materially from those described in the forward-looking statements. These risks and uncertainties include, among others, those relating to our ability to obtain financing and to form collaborative relationships, the effect of a potential delisting of our common stock from The Nasdaq Global Market, uncertainty regarding potential future deterioration in the market for auction rate securities which could negatively affect our cash position and result in additional permanent impairment charges, our ability to develop and market diagnostic products, the level of third party reimbursement for our products, risks related to preclinical and clinical development of pharmaceutical products, including the identification of compounds and the completion of clinical trials, the effect of government regulation and the regulatory approval processes, market acceptance, our ability to obtain and protect intellectual property rights for our products, dependence on collaborative relationships, the effect of competitive products, industry trends and other risks identified in deCODE's filings with the Securities and Exchange Commission, including, without limitation, the risk factors identified in our most recent Annual Report on Form 10-K and any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. deCODE undertakes no obligation to update or alter these forward-looking statements as a result of new information, future events or otherwise.


Edward Farmer Joy Bessenger Gisli Arnason

+354 570 2819 +1 212 481 3891 +354 570 1825

SOURCE deCODE genetics
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. deCODE Launches deCODE BreastCancer(TM), a Genetic Test to Screen for Risk of the Common Forms of Breast Cancer
2. Open Biosystems Launches Decode RNAi Viral Screening Pools for Low-Cost Genome-Scale RNAi Screens
3. deCODE genetics to Webcast Presentation at Piper Jaffray Annual Healthcare Conference
4. deCODE genetics to Webcast Presentation at Lazard Capital Markets Annual Healthcare Conference
5. Wound Management Technologies, Inc. Announces Strategic Plans for Revenue Growth for Year End and 2009
6. Herley Industries, Inc. Engages Jefferies Quarterdeck to Explore Strategic Alternatives
7. ReachMD, LLC Announces New Strategic Partnership With The American Medical Student Association
8. Marex Group Forms Business Development Department and Promotes Three Strategic Employees
9. Covance and Lilly Enter Into a Strategic R&D Collaboration
10. U.S. Preventive Medicine(R) Forms Strategic Alliance with Physicians Planning Group
11. InfoLogix Launches Strategic Mobility Assessment Service for Hospitals
Post Your Comments:
(Date:12/1/2015)... ... 01, 2015 , ... SAN FRANCISCO, Calif. (December 1, 2015) ... has awarded Education and Developmental Therapies (EDT), an Applied Behavior Analysis (ABA) service ... special needs providers that excel in synthesizing the areas of clinical quality, staff ...
(Date:12/1/2015)... ... 2015 , ... PYA’s latest white paper, “ PYA Leadership ... “pain point” for merging or aligning healthcare provider organizations—when mergers and other affiliation ... This quick-read guidance suggests that failing to recognize the power of an effective ...
(Date:12/1/2015)... ... December 01, 2015 , ... Dr. ... a Modern Man for 2015. , Angeleno Magazine is a division of ... Established in 1994, Modern Luxury includes more than 50 magazine titles across 15 ...
(Date:11/30/2015)... ... 2015 , ... Trevor and Taylor Crabb have unveiled an exciting new ... represent the United States. This hybrid crowdfunding campaign is designed to provide ... in addition to offering corporate sponsors with some great marketing deliverables with the brothers ...
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... ... programs of the19th Bi-National Convention of the Federation of Philippine American Chambers of ... in Las Vegas, Nevada. , 1Heart Caregiver Services, as an active delegate ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... UPPSALA, Sweden , December 1, 2015 /PRNewswire/ ... the International Breast Cancer Study Group (IBCSG, Bern ... Brussels ) to be part of a state of ... new cancer drug.  --> --> ... breast cancer being treated with anti-hormonal therapy in combination with ...
(Date:12/1/2015)... December 1, 2015 Biovicas ... Study Group (IBCSG, Bern ) ... i en klinisk studie av palbociclib, ett nytt ... --> Studien, med namn PYTHIA, kommer följa ... läkemedel i kombination med palbociclib, som tillhör klassen ...
(Date:11/30/2015)... , Dec. 1, 2015 Researchers have ... measures body part thickness and checks for motion, positioning ... a feasibility study presented today at the annual meeting ... (RSNA). Steven Don , M.D., ... Washington University School of Medicine in St. ...
Breaking Medicine Technology: